Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (ACTRN12626001266358) titled 'A Study to Test the Safety and Effects of VIAL-IL13xTSLP in Patients with Mild-to-Moderate Asthma' on Oct. 21.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Masking: Blinded (masking used)
Primary Sponsor: Vial Australia Pty Ltd
Condition:
Asthma (Mild-to-moderate)
Asthma (Mild-to-moderate)
Respiratory - Asthma
Intervention:
VIAL-IL13xTSLP or placebo will be administered subcutaneously to patients with mild-to-moderate asthma in up to two cohorts. Each cohort will evaluate a dose regimen selected from the highest dose exposure level(s) determined to b...